Mounjaro™ (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

When will tirzepatide be available?

Tirzepatide was FDA approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

US_cFAQ_TZP001_AVAILABILITY_T2D
US_cFAQ_TZP001_AVAILABILITY_T2D
en-US

See important safety information, including boxed warning, in the attached prescribing information.

Availability

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D).1

Tirzepatide was FDA approved as an adjunct to diet and exercise to improve glycemic control in adults with T2D on May 13.2

Tirzepatide is expected to be available in the U.S. in the coming weeks.2

Reference

1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

2FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Press release. Eli Lilly and Company; May 13, 2022. Accessed May 13, 2022. http://lilly.mediaroom.com/2022-05-13-FDA-approves-Lillys-Mounjaro-TM-tirzepatide-injection,-the-first-and-only-GIP-and-GLP-1-receptor-agonist-for-the-treatment-of-adults-with-type-2-diabetes

Date of Last Review: May 13, 2022


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical